PSivida CEO To Discuss Ocular Drug Delivery In Diabetic Retinopathy At 6th Annual Diabetes Conference January 22 In London

Main Category: Eye Health / Blindness
Also Included In: Diabetes
Article Date: 21 Jan 2010 - 14:00 PDT

email to a friend   printer friendly   opinions  

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

In his presentation Dr. Ashton will describe the barriers to clinically effective therapies in diabetic retinopathy and the difficulty of getting drugs to the back of the eye, where most diabetic eye disease manifests itself. He is expected to discuss emerging drug delivery technologies, including those under development at pSivida, which can help to get drugs directly to the area of the eye where they can be most effective in treating the underlying disease. As part of this presentation, Dr. Ashton is also expected to recap recent top-line results of the Phase 3 FAME™ trials of Iluvien® in patients with diabetic macular edema that were reported last month by pSivida and its licensee, Alimera Sciences.

Also scheduled to address the two-day conference are representatives from GlaxoSmithKline, Sanofi-Aventis, Merck Sharp & Dohme, F. Hoffman-LaRoche, AstraZeneca, Lilly, Astellas, Regeneron Pharmacuegticals, Medpace and Fovea Pharmaceuticals, and leading ophthalmologists from the University of Oxford and Moorfields Eye Hospital.

About Iluvien®

Iluvien is an investigative, extended release intravitreal insert that Alimera is developing for the treatment of DME. Each Iluvien insert is designed to provide a therapeutic effect for up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FA). Iluvien is inserted in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. Iluvien is inserted with a device that employs a 25-gauge needle, which allows for a self-sealing wound.

Source
pSivida Corp.

• Additional
• References
• Citations